James Hueftle
Hematology & Oncology · Anaconda, MTNPI 1528041571
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,250 and has fallen 68.4% since, to $395 in 2025.
Across 159 payments — averaging $32.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- E.r. Squibb & Sons, L.L.C.$632
- Amgen$476
- Johnson & Johnson$315
- EMD Serono, Inc.$286
- Sanofi$220
- plus $2K from 31 others
Across 2 payments — averaging $8692.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
What the payments were for
- Food & beverage$4,80792%
- Education$4158%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $1,062 |
| E.r. Squibb & Sons, L.L.C. | 20 | $632 |
| Amgen | 16 | $476 |
| Johnson & Johnson | 3 | $315 |
| EMD Serono, Inc. | 4 | $286 |
| Sanofi | 9 | $220 |
| GSK | 3 | $199 |
| Merck | 14 | $192 |
| Exelixis Inc. | 3 | $179 |
| Novartis | 8 | $141 |
| Janssen Scientific Affairs, LLC | 2 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Eisai Inc. | 8 | $115 |
| Genentech USA, Inc. | 7 | $105 |
| Bristol Myers Squibb | 1 | $96 |
| Seagen Inc. | 3 | $96 |
| Astellas Pharma US Inc | 5 | $95 |
| Genentech, Inc. | 1 | $95 |
| Pfizer | 7 | $90 |
| Caris MPI, Inc. | 1 | $85 |
| Adaptive Biotechnologies Corporation | 1 | $77 |
| Gilead | 1 | $68 |
| Myriad Genetic Laboratories, Inc. | 1 | $58 |
| Genmab U.S., Inc. | 1 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Tesaro, Inc. | 2 | $29 |
| Novo Nordisk | 2 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $25 |
| Foundation Medicine, Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Bayer | 1 | $12 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,221 in reported general payments places this provider in the 75th percentile of 37 hematology & oncology providers in Montana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 29 | $521,605 |
| ImbruvicaIbrutinib | 25 | $412,913 |
| JakafiRuxolitinib Phosphate | 23 | $383,189 |
| BrukinsaZanubrutinib | 25 | $281,055 |
| Lenalidomide | 16 | $248,894 |
| VenclextaVenetoclax | 18 | $207,892 |
| EliquisApixaban | 145 | $37,117 |
| Imatinib Mesylate | 13 | $26,058 |
| XareltoRivaroxaban | 17 | $6,411 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,770 |
| OxycontinOxycodone Hcl | 13 | $2,933 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 91 | $2,452 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $2,272 |
| Dexlansoprazole DrDexlansoprazole | 12 | $1,802 |
| Oxycodone Hcl | 61 | $1,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $632 | $521,60529 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25 | $412,91325 claims |
| Incyte CorporationJakafi | $14 | $383,18923 claims |
| PfizerEliquis | $90 | $37,117145 claims |
| Johnson & JohnsonXarelto | $315 | $6,41117 claims |
| GSKBreo Ellipta | $199 | $4,77011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 37 hematology & oncology providers in Montana.
Other hematology & oncology in Anaconda
- Patrick CobbBillings$21K
- Thomas WeinerHelena$14K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
- Karl GuterGreat Falls$9K
- Thomas WarrGreat Falls$8K
- Patrick TangGreat Falls$7K
- Jessica KaaeGreat Falls$6K
- Mark HancockBozeman$6K
- Jennifer CarterGreat Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.